ERBB2 and cancer: HER2 somatic alterations have been reported across various human cancer types and are linked with activating functions that drive oncogenesis akin to gene amplification and HER2 protein overexpression, which may similarly confer drug sensitivity to HER2-targeted TKIs [18–20].